BR112022015968A2 - Composições de células t do receptor de antígeno quimérico direcionado a bcma e métodos e usos das mesmas - Google Patents

Composições de células t do receptor de antígeno quimérico direcionado a bcma e métodos e usos das mesmas

Info

Publication number
BR112022015968A2
BR112022015968A2 BR112022015968A BR112022015968A BR112022015968A2 BR 112022015968 A2 BR112022015968 A2 BR 112022015968A2 BR 112022015968 A BR112022015968 A BR 112022015968A BR 112022015968 A BR112022015968 A BR 112022015968A BR 112022015968 A2 BR112022015968 A2 BR 112022015968A2
Authority
BR
Brazil
Prior art keywords
bcma
methods
antigen receptor
cell compositions
compositions
Prior art date
Application number
BR112022015968A
Other languages
English (en)
Portuguese (pt)
Inventor
Amanda SALMON Ruth
Koegel Ashley
Westoby Matthew
Wrangham Briggs Adrian
G Kugler David
Guy Caspary Robert
Chan Calvin
Varun Divya
Germeroth Lothar
Stemberger Christian
Pawel Poltorak Mateusz
Bashour Keenan
Baturevych Oleksandr
Kilavuz Nurgul
Hege Kristen
Burgess Michael
Wu Kaida
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of BR112022015968A2 publication Critical patent/BR112022015968A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022015968A 2020-02-12 2021-02-11 Composições de células t do receptor de antígeno quimérico direcionado a bcma e métodos e usos das mesmas BR112022015968A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062975731P 2020-02-12 2020-02-12
PCT/US2021/017737 WO2021163389A1 (en) 2020-02-12 2021-02-11 Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof

Publications (1)

Publication Number Publication Date
BR112022015968A2 true BR112022015968A2 (pt) 2022-10-11

Family

ID=74860462

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015968A BR112022015968A2 (pt) 2020-02-12 2021-02-11 Composições de células t do receptor de antígeno quimérico direcionado a bcma e métodos e usos das mesmas

Country Status (11)

Country Link
US (1) US20230087953A1 (https=)
EP (1) EP4103203A1 (https=)
JP (1) JP2023519099A (https=)
KR (1) KR20220152227A (https=)
CN (1) CN115361955A (https=)
AU (1) AU2021219764A1 (https=)
BR (1) BR112022015968A2 (https=)
CA (1) CA3170153A1 (https=)
IL (1) IL295381B1 (https=)
MX (1) MX2022009830A (https=)
WO (1) WO2021163389A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
JP7447006B2 (ja) * 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
KR20210113169A (ko) * 2018-11-01 2021-09-15 주노 쎄러퓨티크스 인코퍼레이티드 Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
WO2023196215A1 (en) * 2022-04-05 2023-10-12 Xcell Biosciences, Inc. Cell populations adapted to a tumor microenvironment
WO2024036167A2 (en) * 2022-08-09 2024-02-15 The Trustees Of The University Of Pennyslvania Methods for enhancing the anti-tumor activity of car t cells by co-expression of ch25h
KR20260005874A (ko) * 2023-02-28 2026-01-12 주노 쎄러퓨티크스 인코퍼레이티드 전신 자가면역 질환을 치료하기 위한 세포 요법
WO2025080994A1 (en) * 2023-10-13 2025-04-17 The General Hospital Corporation Chimeric antigen receptor (car)-t cell engaging antibody molecule (team) formulations and pharmaceutical compositions
WO2025098446A1 (zh) * 2023-11-07 2025-05-15 赛斯尔擎生物技术（上海）有限公司 抗bcma单域抗体及其应用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
FR2540122B1 (fr) 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
WO1986002077A1 (en) 1984-10-02 1986-04-10 Meade Harry M Production of streptavidin-like polypeptides
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
EP0700430B1 (en) 1993-06-04 2005-04-20 The United States of America as Represented by the Secretary of the Navy Methods for selectively stimulating proliferation of t cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
CA2211951A1 (en) 1995-02-09 1996-08-15 University Of Washington Modified-affinity streptavidin
WO1997011183A1 (en) 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
US5801115A (en) 1995-09-05 1998-09-01 Kataleuna Gmbh Catalyst composition and methods for using and preparing same
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
ATE186235T1 (de) 1996-04-24 1999-11-15 Claude Fell Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
AU6701498A (en) 1997-03-14 1998-09-29 Trustees Of Boston University Multiflavor streptavidin
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
HK1041454B (en) 1998-12-24 2004-12-31 生物安全股份有限公司 Blood separation system particularly for concentrating hematopoietic stem cells
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
MX2007011218A (es) 2005-03-23 2007-10-17 Biosafe Sa Sistema integrado para colectar, procesar y transplantar subconjuntos de celulas, incluyendo celulas madre adultas para medicina regenerativa.
CA2682527C (en) 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP2406284B9 (en) 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
TR201811128T4 (tr) 2011-07-18 2018-08-27 Iba Gmbh Bir hedef hücrenin tersinir şekilde boyama yöntemi.
KR102134932B1 (ko) 2011-11-11 2020-07-17 프레드 헛친슨 켄서 리서치 센터 암을 위한 사이클린 ａ１―표적화된 ｔ―세포 면역요법
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
RU2746407C1 (ru) 2012-02-23 2021-04-13 Стейдж Селл Терапеутикс Гмбх Хроматографическое выделение клеток и других сложных биологических материалов
SG10201609210SA (en) 2012-05-03 2016-12-29 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US9599590B2 (en) 2012-10-12 2017-03-21 Sage Science, Inc. Side-eluting molecular fractionator
WO2014076277A1 (en) 2012-11-16 2014-05-22 Iba Gmbh Streptavidin muteins and methods of using them
DE112012007250B4 (de) 2012-12-20 2024-10-24 Mitsubishi Electric Corp. Fahrzeuginterne Vorrichtung und Programm
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
BR112016024072B1 (pt) 2014-04-16 2021-02-09 Juno Therapeutics Gmbh método in vitro de estimular uma população de células
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
WO2016061416A1 (en) 2014-10-15 2016-04-21 Sage Science, Inc. Apparatuses, methods and systems for automated processing of nucleic acids and electrophoretic sample preparation
CN107109438B (zh) 2014-11-05 2021-09-03 朱诺治疗学股份有限公司 用于转导及细胞处理的方法
KR20240135036A (ko) 2014-12-05 2024-09-10 메모리얼 슬로안 케터링 캔서 센터 B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
AU2015357526B2 (en) 2014-12-05 2022-03-17 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
EA036379B1 (ru) * 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
US11248238B2 (en) 2015-10-22 2022-02-15 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
SG11201908271WA (en) 2017-03-14 2019-10-30 Juno Therapeutics Inc Methods for cryogenic storage
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
US20200078404A1 (en) * 2017-05-01 2020-03-12 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
CN111263641B (zh) * 2017-08-09 2025-10-31 朱诺治疗学股份有限公司 用于制备基因工程化细胞的方法和组合物
AU2018313950A1 (en) * 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
JP7447006B2 (ja) * 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
SG11202003427XA (en) * 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
CA3084446A1 (en) * 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
WO2019113557A1 (en) * 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
CA3105813A1 (en) * 2018-07-11 2020-01-16 Celgene Corporation Uses of anti-bcma chimeric antigen receptors

Also Published As

Publication number Publication date
CA3170153A1 (en) 2021-08-19
IL295381B1 (en) 2026-04-01
JP2023519099A (ja) 2023-05-10
CN115361955A (zh) 2022-11-18
IL295381A (en) 2022-10-01
KR20220152227A (ko) 2022-11-15
WO2021163389A1 (en) 2021-08-19
AU2021219764A1 (en) 2022-09-01
US20230087953A1 (en) 2023-03-23
MX2022009830A (es) 2022-10-28
EP4103203A1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
BR112022015968A2 (pt) Composições de células t do receptor de antígeno quimérico direcionado a bcma e métodos e usos das mesmas
BR112021010354A2 (pt) Métodos para o tratamento usando terapia celular adotiva
BR112022015236A2 (pt) Composições de células t do receptor de antígeno quimérico direcionado a cd19 e métodos e usos das mesmas
BR112022005423A2 (pt) Interrupção de tecidos tumorais por alvejamento de proteína de ativação de fibroblasto (fap)
Forel et al. Phenotype and functions of natural killer cells in critically-ill septic patients
BR112017008693A2 (pt) célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição.
CO2021012587A2 (es) Receptores de células t mage a4
BR112016028755A2 (pt) anticorpo ou fragmento de ligação ao antígeno macromolécula, molécula de ácido nucleico, composição farmacêutica, antígeno, e, métodos para fabricar um anticorpo e para selecionar um anticorpo.
BR112017003836A2 (pt) processo para sintetizar dna livre de células
BR112019021857A2 (pt) Métodos e composições de célula t aperfeiçoada
BR112017005390A2 (pt) células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
WO2016061456A2 (en) Compositions and methods for identification, assessment, prevention, and treatment of t-cell exhaustion using cd39 biomarkers and modulators
EA201890782A1 (ru) Способ перенацеливания t-клеток для лечения инфекции hiv
CL2021002067A1 (es) Células modificadas por receptor de antígeno quimérico para el tratamiento de cánceres que expresan cldn6.
BR112021024822A2 (pt) Terapia de combinação de terapia citotóxica mediada por células e inibidor de proteína da família bcl2 pró-sobrevivência
BR112021026382A2 (pt) Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer
BR112022019797A2 (pt) Células b modificadas e métodos para uso das mesmas
BR112021018100A2 (pt) Métodos para a diferenciação e expansão de linfócitos t e células nk, para enriquecimento e expansão ex vivo de linfócitos e para tratar um câncer, uso do método, células, e, composição de células
Saeidi et al. Regulation of CD8+ T-cell cytotoxicity in HIV-1 infection
Teege et al. Tuning IL-2 signaling by ADP-ribosylation of CD25
BR112022025026A2 (pt) Ensaio baseado em células para determinar atividade de morte tumoral in vitro de células imunitárias que expressam antigénio quimérico
BR112022014501A2 (pt) Métodos para dosagem e tratamento de linfoma folicular e linfoma de zona marginal em terapia celular adotiva
EP3060924A2 (en) Pif-transfected cells and methods of use
Kielsen et al. Soluble interleukin-7 receptor levels and risk of acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation
CU20220039A7 (es) Combinaciones y kits que incluyen células efectoras inmunitarias modificadas por ingeniería genética para expresar receptores de antígenos